PeterJayVan VeldhuizenMD

PubMed

• 17 citations
  Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
  Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
  Clinical Genitourinary Cancer. 2020-12-01
• 87 citations
  Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.
  Inamul Haque, Smita Mehta, Monami Majumder, Kakali Dhar, Archana De
  Molecular Cancer. 2011-01-13
• 44 citations
  The Matricellular Protein CCN1/Cyr61 Is a Critical Regulator of Sonic Hedgehog in Pancreatic Carcinogenesis *
  Inamul Haque, Archana De, Monami Majumder, Smita Mehta, Douglas H. McGregor
  The Journal of Biological Chemistry. 2012-11-09

Journal Articles

• Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...  
  Goldkorn A, Ely B, Tangen CM, Tai Y, Xu T, Hongli Li, Twardowski P, Van Veldhuizen PJ, Neeraj Agarwal N, Carducci MA, Monk III JP, Garzotto M, Mack PC, Lara Jr. P, Hig..., Journal of Clinical Oncology, 1/10/2013
• Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer  
  Dubey S, Gunewardena S, Van Veldhuizen P, Thrasher JB, Karan D, Journal for Immunotherapy of Cancer, 1/1/2013
• Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy  
  Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators, Eur J Cancer, 1/1/2013
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, place...  
  Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li J..., Lancet Oncol, 1/1/2012
• Adenovirus-based Immunotherapy for Prostate Cancer  
  Dubey S, Van Veldhuizen P, Karan D, Current Cancer Therapy Reviews, 1/1/2012
• Prostate Cancer Immunotherapy: An Evolving Field  
  Hashmi M, Karan D, Phadke S, Saunthararajah Y, Kambhampati S, Van Veldhuizen P, Current Cancer Therapy Reviews, 1/1/2012
• Cancer immunotherapy: a paradigm shift for prostate cancer treatment  
  Karan D, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Nat Rev Urol, 1/1/2012
• Mycobacterium Bovis BCG Strain Osteomyelitis Masquerading as Spinal Metastasis from Bladder Cancer  
  Chuda R, Poddutoori P, Van Veldhuizen P, Kansas Journal of Medicine, 1/1/2012
• Abiraterone and increased survival in metastatic prostate cancer  
  de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Che..., N Engl J Med, 1/26/2011
• Imaging Studies that can be used for complimentary & alternative medicine clinical studies  
  Dusing RW, Drisko JA, Grado GG, Holzbeierlein JM, Van Veldhuizen P, Urology Clinics of North America, 1/1/2011
• Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cellspericytes transition and recruitment through an interaction with NRP-1  
  Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK, Banerjee S., Mol Cancer, 1/1/2010
• S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5-Fluorouracil, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach  
  Blanke CD, Chansky K, Christman KL, Hundahl SA, Issel BF, Van Veldhuizen PJ, et al, Am Journal of Clinical Oncology, 1/1/2010
• Results of the Southwest Oncology Group phase II evaluation of ZD1839 for advanced transitional cell carcinoma of the urothelium  
  Petrylak DP, Tangen CM, Van Veldhuizen PJ, et al, 1/1/2010
• 2-Methoxyestradiol inhibits barrett’s esophageal adenocarcinoma growth and differentiation through differential regulation of the betacatenin-E-caderin axis  
  Kambhampati S, Banerjee S, Dhar K, Mehta S, Haque I, Dhar G, Majumder M, Ray G, Van Veldhuizen PJ, Banerjee SK, Mol Cancer Ther, 1/1/2010
• Phase II Study of darinaparsin in patients with advanced hepatocellular carcinoma  
  Wu J, Henderson C, Feun L, Van Veldhuizen P, et al, Investigational New Drugs, 1/30/2009
• A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients with Advanced Renal Cell Cancer (RCC): Southwest Oncology Group Study 0312  
  Van Veldhuizen PJ, Hussey M, Primo NL Jr, Gumerlock PH, Clark J, Lange MK, Crawford DE, Am J Clin Oncol, 1/29/2009
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy  
  Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, et al, Journal of Urology, 1/1/2009
• Managing Adverse Effects of Newer Therapies for Advanced Disease  
  Haideri N, Keefe S, Atherton C and Van Veldhuizen P, Federal Practitioner, 1/1/2009
• Treatment Options for Unresectable Disease  
  Mirza M and Van Veldhuizen P, Federal Practitioner, 1/1/2009
• Gain of function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2  
  Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Van Veldhuizen PJ, Banerjee SK, Cancer Res, 1/1/2009
• 2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2- methoxyestradiol-induced inhibition of cell growth  
  Van Veldhuizen PJ, Ray G, Banerjee S, Dhar G, Kambhampati S, Dhar A, Banerjee SK, Int J Cancer, 1/1/2009
• Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer (AIPC) Previously Treated with Taxanes: Southwest Oncology Group Study  
  Beer TM, Goldman, B, Synold, Timothy W, Synold, Ryan CW, Lakshmi SV, Van Veldhuizen P, Dakhil S, Gandara DR, Drelichman A, Raghavan DR, Hussein M, Crawford DE, Clin Genitourin Cancer, 1/1/2008
• Dysgenetic Hypoplastic Kidney Simulating Lung Carcinoma  
  Huang C, McGregor D, Haltaufderhyde V, Victor F, Van Veldhuizen P, Lung Cancer, 1/1/2007
• Biclonal Post-Transplant B-cell Lymphoma: report of a case with two distinct cell populations-XX, t(14;18) and XY,t(11;14)  
  Dennis KL, Wallentine SL, Van Veldhuizen PJ, Persons DL, Mathur S, Cancer Genetics and Cytogenetics, 1/1/2007
• The Validity of the Dissociative Disorders (Letter to the Editor)  
  Van Veldhuizen PJ, Comphrensive Psychiatry, 1/1/2007
• Join now to see all

Books/Book Chapters

• Current Cancer Therapy Reviews 
  Chapter: Prostate Cancer Immunotherapy 
  Karan D, Van Veldhuizen P2012
• Anti-Angiogenic and Medicinal Foods 
  Chapter: Angiogenic Switch: Roles of Estrogenic Compounds 
  Page 358 - 371Banerjee SK, Ray G, Van Veldhuizen P, Banerjee S2007
• Comprehensive Textbook of Genitourinary Oncology 
  Chapter: Seminoma: Management of Stage II Disease, Posttherapy residual masses and other special considerations 
  Smalley S, Van Veldhuizen PJ1998

Abstracts/Posters

• In vitro efficacy of MAGMAS inhibition in prostate cancer
  Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, ASCO; Genitourinary Cancers Symposium, 1/30/2014
• Applicability of MIC-1 as a potential biomarker for racial disparity in prostate cancer
  Dubey S, Wick J, Tawfik, O, Zainfeld D, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Karan D, AUA Annual Meeting, Orlando, FL, 1/16/2014
• MAGMAS inhibition in hepatocellular carcinoma
  Das BC, Powers BC, Bouzahzah B, Borrego-Diaz E, Van Veldhuizen PJ, 248th ACS National Meeting, 1/10/2014
• Repurposing Drugs in Hepatocellular Carcinoma
  Powers BC, Bouzahzah B, Diaz F, Hunt S, Van Veldhuizen P, Borrego-Diaz Reyes E, Translational Science, Omni Shoreham, Washington, DC, 1/1/2014
• SIRT1 as a potential therapeutic target in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Powers BC, Diaz F, Azizov V, Kasi Loknath Kumar A, Sharma M, Van Veldhuizen P, Translational Science, Omni Shoreham, Washington, DC, 1/1/2014
• Applicability of MIC-1 as a potential biomarker for racial disparity in prostate cancer
  Zainfeld D, Dubey S, Wick Jo, Holzbeierlein J, Van Veldhuizen P, Thrasher JB, Karan D, SCS/AUA 92nd Annual Meeting, Chicago, IL, 1/18/2013
• Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer
  Dubey S, Gunewardena S, Van Veldhuizen P, Thrasher JB and Karan D, Society for Immunotherapy of Cancer; 28th Annual Meeting, 1/8/2013
• The effect of short-term soy isoflavone supplementation on gene transcripts and biochemical recurrence after curative treatment for localized prostate cancer
  Hamilton-Reeves J, Rubin JD, Camey SC, Godwin AK, Griffin JG, Chalise P, Van Veldhuizen P, AICR, 1/1/2013
• Effect of Denosumab on prolonging bone metastasis free survival (BMFS) in men with non metastatic castrate resistant prostate cancer (CRPC) presenting with aggressive ...
  Van Veldhuizen P, Smith MR, Saad F, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Damiao R, Marx G, Morote J, Zhishen Ye, Dansey R, Goessl C, AUA South Central Sectional, 1/24/2012
• Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of G-CSF: a potential neoplastic marker?
  Kumar AKL, Holzbeierlein J, Van Veldhuizen P, National ACP Meeting, 1/1/2012
• Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive P...
  Saad F, Smith MR, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen P, Damiao R, Marx G, Morote J, Ye Z, Dansey R, Goessl CD, J Clin Oncol, 1/1/2012
• SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC)
  Quinn D, Tangen C, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Carducci A, Monk JP, Twardowski P, Van Veldhuizen P, Agarwal N, Higano CS, Vogelzang NJ, Thomps..., J Clin Oncol, 1/1/2012
• Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421)
  Goldkorn A, Ely B, Quinn D, Tangen C, Yu-Chong Tai, Twardowski P, Van Veldhuizen P, Agarwal N, Carducci A, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, ..., J Clin Oncol, 1/1/2012
• Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prost...
  Vogelzang NJ, Ely B, Louis M. Fink, Goldkorn A, Tangen C, Twardowski P, Van Veldhuizen P, Agarwal N, Carducci A, Monk JP, Ram H Datar, Garzotto M, Mack PC, Lara P, Hig..., J Clin Oncol, 1/1/2012
• Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutic...
  Sarantopoulos J, Hoering A, Synold TW, Mahalingam D, Wang D, Lenz HJ, O’Rourke P, Sexton R, Van Veldhuizen P, Mita M, Wong L, Mita AC, El-Khoueiry A, Chung VM, Gandar..., J Clin Oncol, 1/1/2012
• Docetaxel followed by temsirolimus in suppression of mTOR pathway
  Huang C, Van Veldhuizen P, Gadashova A, Williamson SK, Farassati F, J Clin Oncol, 1/1/2012
• Sequential docetaxel followed by mTOR inhibitor temsirolimus can suppress PI3K over-activation resistance mechanism
  Huang C, Van Veldhuizen P, Gadashova A, Williamson SK, Farassati F, Markers in Cancer Conference, 1/1/2012
• Denosumab and bone metastasis-free survival in men with castrate-resistant prostate cancer: subgroup analyses from an international, double-blind, randomized, phase 3 ...
  Wong S, Smith M, Oudard S, Karsh L, Egerdie B, Van Veldhuizen P, Gomez-Veiga F, Dearnaley D, Fisher H, Wirth M, Charu V, Kuepper F, Montes de Oca L, Rendon R, Julka PK..., ISOPP Meeting, 1/1/2012
• Denosumab Delays Development of Multiple Bone Metastases in Men With Castration-Resistant Prostate Cancer
  Smith MR, Saad F, Shore N, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen P, Damiao R, Marx G, Morote J, Feng A, Dansey R, Goessl C, AUA Meeting, 1/1/2012
• A QTc study of cabazitaxel in patients with advanced solid tumors
  Wade JL, Dakhil S, Baron A, Rottey S, Millard FE, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw P, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, TX..., J Clin Oncol, 1/1/2012
• MK-0646 (MK), insulin growth factor 1 receptor (IGF-1R) antibody combined with pemetrexed (P) and cisplatin (C) in stage IIIb or IV metastatic nonsquamous lung cancer ...
  Huang C, Kelly K, Williamson SK, Neupane P, Taylor SA, Allen A, Wick J, Van Veldhuizen P, J Clin Oncol, 1/1/2012
• Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive P...
  Smith MR, Saad F, Shore ND, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen PJ, Damião R, Marx GM, Morote J, Feng A, Dansey R, Dietrich Goessl C, J Clin Oncol; Genitourinary Cancers Symposium, 1/1/2012
• Lin28B as a master oncogene regulator in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Kambhampati S, Azizov V, Reyes R, Banerjee S, Haideri N, Power B, Wang X, Godwin A, Banerjee S and Van Veldhuizen P, MBRF meeting, 1/1/2012
• MicroRNA profiling in 2ME2 exposes Barrett’s esophageal cells
  Borrego-Diaz E, Azizov V, Banerjee S, Haque I, Power B, Wang X, Van Veldhuizen P, Banerjee S, Kambhampati S, MBRF meeting, 1/1/2012
• 2ME2 regulates microRNA expression throughout Lin28B pathway in androgen independent prostate cancer
  Borrego-Diaz Reyes E, Kambhampati S, Azizov V, Banerjee S, Haque I, Haideri N, Power B, Wang X, Sand B, Van Veldhuizen P, MBRF meeting, 1/1/2012
• Join now to see all